DALLAS - Celanese Corporation (NYSE:CE), a global chemical and specialty materials company, has announced the launch of iDose TR, a product utilizing its proprietary VitalDose EVA for the sustained release of medication to treat glaucoma.
This new treatment option, developed in collaboration with Glaukos (NYSE:GKOS) Corporation, aims to address the issue of patient non-compliance with traditional eye-drop treatments by providing a continuous dosing method.
The FDA approved iDose TR in December 2023 as a first-of-its-kind therapy that delivers a proprietary formulation of travoprost directly into the eye. The approval was based on the results of two pivotal trials involving 1,150 subjects, which demonstrated the safety and efficacy of the product.
The travoprost is delivered through a nanoporous membrane created using VitalDose EVA, a platform capable of being formulated into various form factors to meet different drug delivery needs.
Cyonna Holmes, global business strategy leader for Ophthalmology and RNA at Celanese, stated that the company is excited to support Glaukos in transforming the glaucoma treatment landscape. She emphasized the unmet need in ophthalmology for therapies that improve patient compliance and reduce the burden of treatment.
VitalDose EVA has a history of use in approved parenteral drug products in the United States and Europe, known for its reliable, controlled-release performance. iDose TR is specifically indicated for reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension. It is administered intracamerally under aseptic conditions and is not recommended for patients with certain ocular conditions or hypersensitivity to travoprost.
Celanese, a Fortune 500 company, reported net sales of $10.9 billion in 2023 and employs approximately 12,400 people worldwide. This article is based on a press release statement from Celanese Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.